Mitoxantrone, approved by the US FDA as a USP11 inhibitor, is undergoing numerous phase I/II trials targeting conditions including neoplasms, acute myeloid leukemia, MS, and breast cancer.469. This evidence concerns the gene USP11 and neoplasm.